PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.68%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-2.68%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-2.79%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
1.20%
Positive EPS growth while AGEN is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
2.99%
Positive diluted EPS growth while AGEN is negative. John Neff might view this as a strong relative advantage in controlling dilution.
3.80%
Share count expansion well above AGEN's 6.21%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
6.10%
Diluted share count expanding well above AGEN's 6.21%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
35.18%
Positive OCF growth while AGEN is negative. John Neff would see this as a clear operational advantage vs. the competitor.
35.60%
Positive FCF growth while AGEN is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13691.29%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
29.84%
Positive OCF/share growth while AGEN is negative. John Neff might see a comparative advantage in operational cash viability.
58.26%
Positive 3Y OCF/share CAGR while AGEN is negative. John Neff might see a big short-term edge in operational efficiency.
-7976.92%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
76.35%
Positive 5Y CAGR while AGEN is negative. John Neff might view this as a strong mid-term relative advantage.
62.71%
Positive short-term CAGR while AGEN is negative. John Neff would see a clear advantage in near-term profit trajectory.
1259.19%
Positive growth while AGEN is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
224.33%
Positive 5Y equity/share CAGR while AGEN is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
-84.52%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-5.18%
Negative asset growth while AGEN invests at 4.54%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-26.68%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
20.47%
R&D growth drastically higher vs. AGEN's 20.69%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
-32.93%
We cut SG&A while AGEN invests at 5.65%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.